- Home
- SOLV vs EXEL Comparison
SOLV vs EXEL Comparison
Compare SOLV & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- EXEL
- Stock Information
- Founded
- SOLV 2023
- EXEL 1994
- Country
- SOLV United States
- EXEL United States
- Employees
- SOLV N/A
- EXEL N/A
- Industry
- SOLV
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOLV
- EXEL Health Care
- Exchange
- SOLV NYSE
- EXEL Nasdaq
- Market Cap
- SOLV 12.7B
- EXEL 12.0B
- IPO Year
- SOLV N/A
- EXEL 2000
- Fundamental
- Price
- SOLV $73.29
- EXEL $44.47
- Analyst Decision
- SOLV Hold
- EXEL Buy
- Analyst Count
- SOLV 11
- EXEL 18
- Target Price
- SOLV $83.57
- EXEL $44.24
- AVG Volume (30 Days)
- SOLV 756.5K
- EXEL 3.6M
- Earning Date
- SOLV 08-07-2025
- EXEL 07-28-2025
- Dividend Yield
- SOLV N/A
- EXEL N/A
- EPS Growth
- SOLV N/A
- EXEL 237.58
- EPS
- SOLV 2.18
- EXEL 2.20
- Revenue
- SOLV $8,308,000,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- SOLV $4.11
- EXEL $9.93
- Revenue Next Year
- SOLV $0.14
- EXEL $13.17
- P/E Ratio
- SOLV $33.68
- EXEL $20.18
- Revenue Growth
- SOLV 1.29
- EXEL 24.49
- 52 Week Low
- SOLV $52.40
- EXEL $22.20
- 52 Week High
- SOLV $85.92
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- EXEL 53.42
- Support Level
- SOLV N/A
- EXEL $44.03
- Resistance Level
- SOLV N/A
- EXEL $45.52
- Average True Range (ATR)
- SOLV 0.00
- EXEL 1.44
- MACD
- SOLV 0.00
- EXEL -0.06
- Stochastic Oscillator
- SOLV 0.00
- EXEL 22.78
About SOLV SOLVENTUM CORP
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.